{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:19:40Z","timestamp":1787008780181,"version":"build-2736575974"},"reference-count":55,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T00:00:00Z","timestamp":1687824000000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Netherlands CardioVascular Research Initiative","award":["CVON-PREDICT2 2018-30"],"award-info":[{"award-number":["CVON-PREDICT2 2018-30"]}]},{"name":"Netherlands CardioVascular Research Initiative","award":["CVON-eDETECT 2015-12"],"award-info":[{"award-number":["CVON-eDETECT 2015-12"]}]},{"DOI":"10.13039\/501100001674","name":"Fondation Leducq","doi-asserted-by":"publisher","award":["17CVD02"],"award-info":[{"award-number":["17CVD02"]}],"id":[{"id":"10.13039\/501100001674","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ZonMw Priority Medicines","award":["113303006"],"award-info":[{"award-number":["113303006"]}]},{"name":"ZonMw PSIDER"},{"DOI":"10.13039\/100018767","name":"DECIPHER","doi-asserted-by":"publisher","award":["10250042110010"],"award-info":[{"award-number":["10250042110010"]}],"id":[{"id":"10.13039\/100018767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Foundation","doi-asserted-by":"publisher","award":["NNF21CC0073729"],"award-info":[{"award-number":["NNF21CC0073729"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>SCN5A mutations are associated with various cardiac phenotypes, including long QT syndrome type 3 (LQT3), Brugada syndrome (BrS), and cardiac conduction disease (CCD). Certain mutations, such as SCN5A-1795insD, lead to an overlap syndrome, with patients exhibiting both features of BrS\/CCD [decreased sodium current (INa)] and LQT3 (increased late INa). The sodium channel blocker mexiletine may acutely decrease LQT3-associated late INa and chronically increase peak INa associated with SCN5A loss-of-function mutations. However, most studies have so far employed heterologous expression systems and high mexiletine concentrations. We here investigated the effects of a therapeutic dose of mexiletine on the mixed phenotype associated with the SCN5A-1795insD mutation in HEK293A cells and human-induced pluripotent stem cell\u2013derived cardiomyocytes (hiPSC-CMs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>To assess only the chronic effects on trafficking, HEK293A cells transfected with wild-type (WT) SCN5A or SCN5A-1795insD were incubated for 48\u2005h with 10\u2005\u00b5m mexiletine followed by wash-out, which resulted in an increased peak INa for both SCN5A-WT and SCN5A-1795insD and an increased late INa for SCN5A-1795insD. Acute re-exposure of HEK293A cells to 10\u2005\u00b5m mexiletine did not impact on peak INa but significantly decreased SCN5A-1795insD late INa. Chronic incubation of SCN5A-1795insD hiPSC-CMs with mexiletine followed by wash-out increased peak INa, action potential (AP) upstroke velocity, and AP duration. Acute re-exposure did not impact on peak INa or AP upstroke velocity, but significantly decreased AP duration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings demonstrate for the first time the therapeutic benefit of mexiletine in a human cardiomyocyte model of SCN5A overlap syndrome.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/europace\/euad154","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T03:50:58Z","timestamp":1686196258000},"source":"Crossref","is-referenced-by-count":19,"title":["Beneficial effects of chronic mexiletine treatment in a human model of\n                    <i>SCN5A<\/i>\n                    overlap syndrome"],"prefix":"10.1093","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8485-4446","authenticated-orcid":false,"given":"Giovanna","family":"Nasilli","sequence":"first","affiliation":[{"name":"Department of Experimental Cardiology, Amsterdam University Medical Center, University of Amsterdam , Heart Centre, Meibergdreef 9, 1105 AZ, Amsterdam , The Netherlands"},{"name":"Amsterdam Cardiovascular Sciences, Heart Failure & Arrhythmias , Amsterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1477-005X","authenticated-orcid":false,"given":"Loukia","family":"Yiangou","sequence":"additional","affiliation":[{"name":"Department of Anatomy and Embryology, Leiden University Medical Center , Albinusdreef 2, 2300 RC, Leiden , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6286-8089","authenticated-orcid":false,"given":"Chiara","family":"Palandri","sequence":"additional","affiliation":[{"name":"Department NeuroFarBa, University of Florence , Viale Gaetano Pieraccini 6, 50139, Florence , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7839-1361","authenticated-orcid":false,"given":"Elisabetta","family":"Cerbai","sequence":"additional","affiliation":[{"name":"Department NeuroFarBa, University of Florence , Viale Gaetano Pieraccini 6, 50139, Florence , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7917-9423","authenticated-orcid":false,"given":"Richard P","family":"Davis","sequence":"additional","affiliation":[{"name":"Department of Anatomy and Embryology, Leiden University Medical Center , Albinusdreef 2, 2300 RC, Leiden , The Netherlands"},{"name":"The Novo Nordisk Foundation Center for Stem Cell Medicine (reNEW) , Albinusdreef 2, 2300 RC, Leiden , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2140-834X","authenticated-orcid":false,"given":"Arie O","family":"Verkerk","sequence":"additional","affiliation":[{"name":"Department of Experimental Cardiology, Amsterdam University Medical Center, University of Amsterdam , Heart Centre, Meibergdreef 9, 1105 AZ, Amsterdam , The Netherlands"},{"name":"Amsterdam Cardiovascular Sciences, Heart Failure & Arrhythmias , Amsterdam , The Netherlands"},{"name":"Department of Medical Biology, Amsterdam University Medical Center, University of Amsterdam , Meibergdreef 9, 1105 AZ, Amsterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2672-2779","authenticated-orcid":false,"given":"Simona","family":"Casini","sequence":"additional","affiliation":[{"name":"Department of Experimental Cardiology, Amsterdam University Medical Center, University of Amsterdam , Heart Centre, Meibergdreef 9, 1105 AZ, Amsterdam , The Netherlands"},{"name":"Amsterdam Cardiovascular Sciences, Heart Failure & Arrhythmias , Amsterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0095-0084","authenticated-orcid":false,"given":"Carol Ann","family":"Remme","sequence":"additional","affiliation":[{"name":"Department of Experimental Cardiology, Amsterdam University Medical Center, University of Amsterdam , Heart Centre, Meibergdreef 9, 1105 AZ, Amsterdam , The Netherlands"},{"name":"Amsterdam Cardiovascular Sciences, Heart Failure & Arrhythmias , Amsterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,6,27]]},"reference":[{"key":"2023062723545057100_euad154-B1","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1152\/physrev.00002.2005","article-title":"Molecular physiology of cardiac repolarization","volume":"85","author":"Nerbonne","year":"2005","journal-title":"Physiol Rev"},{"key":"2023062723545057100_euad154-B2","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1093\/europace\/euac218","article-title":"Familial atrial fibrillation mutation M1875T-SCN5A increases early sodium current and dampens the effect of flecainide","volume":"25","author":"O'Reilly","year":"2023","journal-title":"Europace"},{"key":"2023062723545057100_euad154-B3","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1093\/europace\/euac090","article-title":"The G213D variant in Nav1.5 alters sodium current and causes an arrhythmogenic phenotype resulting in a multifocal ectopic Purkinje-related premature contraction phenotype in human-induced pluripotent stem cell-derived cardiomyocytes","volume":"24","author":"Calloe","year":"2022","journal-title":"Europace"},{"key":"2023062723545057100_euad154-B4","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1755-5922.2010.00210.x","article-title":"Sodium channel (dys)function and cardiac arrhythmias","volume":"28","author":"Remme","year":"2010","journal-title":"Cardiovasc Ther"},{"key":"2023062723545057100_euad154-B5","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.RES.85.12.1206","article-title":"A single Na(+) channel mutation causing both long-QT and Brugada syndromes","volume":"85","author":"Bezzina","year":"1999","journal-title":"Circ Res"},{"key":"2023062723545057100_euad154-B6","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1161\/CIRCULATIONAHA.106.653949","article-title":"Overlap syndrome of cardiac sodium channel disease in mice carrying the equivalent mutation of human SCN5A-1795insD","volume":"114","author":"Remme","year":"2006","journal-title":"Circulation"},{"key":"2023062723545057100_euad154-B7","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1161\/CIRCULATIONAHA.111.066092","article-title":"Cardiomyocytes derived from pluripotent stem cells recapitulate electrophysiological characteristics of an overlap syndrome of cardiac sodium channel disease","volume":"125","author":"Davis","year":"2012","journal-title":"Circulation"},{"key":"2023062723545057100_euad154-B8","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1161\/01.CIR.101.6.616","article-title":"Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome","volume":"101","author":"Moss","year":"2000","journal-title":"Circulation"},{"key":"2023062723545057100_euad154-B9","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1001\/jama.292.11.1341","article-title":"Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers","volume":"292","author":"Priori","year":"2004","journal-title":"Jama-J Am Med Assoc"},{"key":"2023062723545057100_euad154-B10","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1093\/eurheartj\/ehy247","article-title":"A common co-morbidity modulates disease expression and treatment efficacy in inherited cardiac sodium channelopathy","volume":"39","author":"Rivaud","year":"2018","journal-title":"Eur Heart J"},{"key":"2023062723545057100_euad154-B11","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1093\/europace\/euac087","article-title":"Effectiveness and safety of mexiletine in patients at risk for (recurrent) ventricular arrhythmias: a systematic review","volume":"24","author":"van der Ree","year":"2022","journal-title":"Europace"},{"key":"2023062723545057100_euad154-B12","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1093\/europace\/euac101","article-title":"Mexiletine for recurrent ventricular tachycardia in adult patients with structural heart disease and implantable cardioverter defibrillator: an EHRA systematic review","volume":"24","author":"Farkowski","year":"2022","journal-title":"Europace"},{"key":"2023062723545057100_euad154-B13","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jacbts.2019.06.002","article-title":"A molecularly detailed Na(V)1.5 model reveals a new class I antiarrhythmic target","volume":"4","author":"Moreno","year":"2019","journal-title":"JACC Basic Transl Sci"},{"key":"2023062723545057100_euad154-B14","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0008-6363(02)00445-5","article-title":"A novel SCN5A arrhythmia mutation, M1766L, with expression defect rescued by mexiletine","volume":"55","author":"Valdivia","year":"2002","journal-title":"Cardiovasc Res"},{"key":"2023062723545057100_euad154-B15","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.cardiores.2004.01.022","article-title":"A trafficking defective, Brugada syndrome-causing SCN5A mutation rescued by drugs","volume":"62","author":"Valdivia","year":"2004","journal-title":"Cardiovasc Res"},{"key":"2023062723545057100_euad154-B16","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1161\/CIRCRESAHA.110.218891","article-title":"Trafficking defects and gating abnormalities of a novel SCN5A mutation question gene-specific therapy in long QT syndrome type 3","volume":"106","author":"Ruan","year":"2010","journal-title":"Circ Res"},{"key":"2023062723545057100_euad154-B17","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3389\/fphar.2012.00062","article-title":"Mexiletine differentially restores the trafficking defects caused by two Brugada syndrome mutations","volume":"3","author":"Moreau","year":"2012","journal-title":"Front Pharmacol"},{"key":"2023062723545057100_euad154-B18","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1080\/19336950.2018.1475794","article-title":"Mexiletine rescues a mixed biophysical phenotype of the cardiac sodium channel arising from the SCN5A mutation, N406K, found in LQT3 patients","volume":"12","author":"Hu","year":"2018","journal-title":"Channels (Austin)"},{"key":"2023062723545057100_euad154-B19","doi-asserted-by":"crossref","first-page":"374","DOI":"10.2165\/00003495-199040030-00005","article-title":"Mexiletine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias","volume":"40","author":"Monk","year":"1990","journal-title":"Drugs"},{"key":"2023062723545057100_euad154-B20","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1113\/jphysiol.2001.012541","article-title":"Mexiletine block of disease-associated mutations in S6 segments of the human skeletal muscle Na(+) channel","volume":"537","author":"Takahashi","year":"2001","journal-title":"J Physiol"},{"key":"2023062723545057100_euad154-B21","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1113\/jphysiol.2003.054973","article-title":"Mexiletine block of wild-type and inactivation-deficient human skeletal muscle hNav1.4 Na+ channels","volume":"554","author":"Wang","year":"2004","journal-title":"J Physiol"},{"key":"2023062723545057100_euad154-B22","doi-asserted-by":"crossref","first-page":"101698","DOI":"10.1016\/j.scr.2019.101698","article-title":"Cryopreservation of human pluripotent stem cell-derived cardiomyocytes is not detrimental to their molecular and functional properties","volume":"43","author":"van den Brink","year":"2020","journal-title":"Stem Cell Res"},{"key":"2023062723545057100_euad154-B23","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/FJC.0000000000000955","article-title":"Dynamic clamp in electrophysiological studies on stem cell-derived cardiomyocytes-why and how?","volume":"77","author":"Verkerk","year":"2021","journal-title":"J Cardiovasc Pharm"},{"key":"2023062723545057100_euad154-B24","first-page":"7","article-title":"Ion channelopathies in human induced pluripotent stem cell derived cardiomyocytes: a dynamic clamp study with virtual IK1","volume":"6","author":"van Putten","year":"2015","journal-title":"Front Physiol"},{"key":"2023062723545057100_euad154-B25","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/BF01870526","article-title":"Liquid junction potentials and small cell effects in patch-clamp analysis","volume":"121","author":"Barry","year":"1991","journal-title":"J Membr Biol"},{"key":"2023062723545057100_euad154-B26","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s10557-019-06925-6","article-title":"Absence of functional Na(v)1.8 channels in non-diseased atrial and ventricular cardiomyocytes","volume":"33","author":"Casini","year":"2019","journal-title":"Cardiovasc Drugs Ther"},{"key":"2023062723545057100_euad154-B27","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1161\/01.CIR.92.12.3381","article-title":"Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy","volume":"92","author":"Schwartz","year":"1995","journal-title":"Circulation"},{"key":"2023062723545057100_euad154-B28","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1161\/01.CIR.96.6.2038","article-title":"Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade des pointes in LQT2 and LQT3 models of the long-QT syndrome","volume":"96","author":"Shimizu","year":"1997","journal-title":"Circulation"},{"key":"2023062723545057100_euad154-B29","first-page":"316","article-title":"Effect of mexiletine on long QT syndrome model","volume":"24","author":"Wang","year":"2003","journal-title":"Acta Pharmacol Sin"},{"key":"2023062723545057100_euad154-B30","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jacc.2015.12.033","article-title":"Gene-specific therapy with mexiletine reduces arrhythmic events in patients with long QT syndrome type 3","volume":"67","author":"Mazzanti","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2023062723545057100_euad154-B31","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.yjmcc.2017.10.002","article-title":"Sodium channel current loss of function in induced pluripotent stem cell-derived cardiomyocytes from a Brugada syndrome patient","volume":"114","author":"Selga","year":"2018","journal-title":"J Mol Cell Cardiol"},{"key":"2023062723545057100_euad154-B32","doi-asserted-by":"crossref","first-page":"e00160","DOI":"10.1002\/prp2.160","article-title":"Inhibition of hERG potassium channel by the antiarrhythmic agent mexiletine and its metabolite m-hydroxymexiletine","volume":"3","author":"Gualdani","year":"2015","journal-title":"Pharmacol Res Perspect"},{"key":"2023062723545057100_euad154-B33","doi-asserted-by":"crossref","first-page":"128162","DOI":"10.1016\/j.bmcl.2021.128162","article-title":"Human iPSC-derived cardiomyocytes and pyridyl-phenyl mexiletine analogs","volume":"46","author":"Johnson","year":"2021","journal-title":"Bioorg Med Chem Lett"},{"key":"2023062723545057100_euad154-B34","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.vascn.2017.10.005","article-title":"In silico assessment of the effects of various compounds in MEA\/hiPSC-CM assays: modeling and numerical simulations","volume":"89","author":"Abbate","year":"2018","journal-title":"J Pharmacol Toxicol Methods"},{"key":"2023062723545057100_euad154-B35","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.reth.2018.12.002","article-title":"Inhibitory effects of class I antiarrhythmic agents on Na(+) and Ca(2+) currents of human iPS cell-derived cardiomyocytes","volume":"10","author":"Yonemizu","year":"2019","journal-title":"Regen Ther"},{"key":"2023062723545057100_euad154-B36","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/0024-3205(86)90552-7","article-title":"Comparison of the inhibitory effects of mexiletine and lidocaine on the calcium current of single ventricular cells","volume":"39","author":"Ono","year":"1986","journal-title":"Life Sci"},{"key":"2023062723545057100_euad154-B37","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.cardiores.2007.08.005","article-title":"Characterization of a novel SCN5A mutation associated with Brugada syndrome reveals involvement of DIIIS4\u2013S5 linker in slow inactivation","volume":"76","author":"Casini","year":"2007","journal-title":"Cardiovasc Res"},{"key":"2023062723545057100_euad154-B38","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1085\/jgp.201210899","article-title":"Induced pluripotent stem cells used to reveal drug actions in a long QT syndrome family with complex genetics","volume":"141","author":"Terrenoire","year":"2013","journal-title":"J Gen Physiol"},{"key":"2023062723545057100_euad154-B39","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/cvr\/cvx077","article-title":"Anti-arrhythmic potential of the late sodium current inhibitor GS-458967 in murine Scn5a-1798insD+\/- and human SCN5A-1795insD+\/- iPSC-derived cardiomyocytes","volume":"113","author":"Portero","year":"2017","journal-title":"Cardiovasc Res"},{"key":"2023062723545057100_euad154-B40","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/bs.ctm.2016.05.001","article-title":"Cardiac Na channels: structure to function","volume":"78","author":"DeMarco","year":"2016","journal-title":"Curr Top Membr"},{"key":"2023062723545057100_euad154-B41","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.3389\/fphar.2020.01182","article-title":"Gating properties of mutant sodium channels and responses to sodium current inhibitors predict mexiletine-sensitive mutations of long QT syndrome 3","volume":"11","author":"Li","year":"2020","journal-title":"Front Pharmacol"},{"key":"2023062723545057100_euad154-B42","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1124\/mol.118.114025","article-title":"Mexiletine block of voltage-gated sodium channels: isoform- and state-dependent drug-pore interactions","volume":"95","author":"Nakagawa","year":"2019","journal-title":"Mol Pharmacol"},{"key":"2023062723545057100_euad154-B43","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1172\/JCI119335","article-title":"Pharmacological targeting of long QT mutant sodium channels","volume":"99","author":"Wang","year":"1997","journal-title":"J Clin Invest"},{"key":"2023062723545057100_euad154-B44","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1161\/CIRCRESAHA.118.314050","article-title":"Predicting patient response to the antiarrhythmic mexiletine based on genetic variation","volume":"124","author":"Zhu","year":"2019","journal-title":"Circ Res"},{"key":"2023062723545057100_euad154-B45","doi-asserted-by":"crossref","first-page":"12997","DOI":"10.1038\/s41598-019-49450-0","article-title":"Characterization of a novel LQT3 variant with a selective efficacy of mexiletine treatment","volume":"9","author":"Kim","year":"2019","journal-title":"Sci Rep"},{"key":"2023062723545057100_euad154-B46","doi-asserted-by":"crossref","first-page":"107125","DOI":"10.1016\/j.vascn.2021.107125","article-title":"Reliable identification of cardiac conduction abnormalities in drug discovery using automated patch clamp II: best practices for Nav1.5 peak current in a high throughput screening environment","volume":"112","author":"Rotordam","year":"2021","journal-title":"J Pharmacol Toxicol Methods"},{"key":"2023062723545057100_euad154-B47","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1212\/WNL.57.10.1849","article-title":"Gating of myotonic Na channel mutants defines the response to mexiletine and a potent derivative","volume":"57","author":"Desaphy","year":"2001","journal-title":"Neurology"},{"key":"2023062723545057100_euad154-B48","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1152\/jn.00117.2007","article-title":"Lidocaine promotes the trafficking and functional expression of Na(v)1.8 sodium channels in mammalian cells","volume":"98","author":"Zhao","year":"2007","journal-title":"J Neurophysiol"},{"key":"2023062723545057100_euad154-B49","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3389\/fphys.2013.00386","article-title":"Pharmacological rescue of trafficking-impaired ATP-sensitive potassium channels","volume":"4","author":"Martin","year":"2013","journal-title":"Front Physiol"},{"key":"2023062723545057100_euad154-B50","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.bbrc.2012.04.153","article-title":"A422t mutation in HERG potassium channel retained in ER is rescurable by pharmacologic or molecular chaperones","volume":"422","author":"Guo","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"2023062723545057100_euad154-B51","doi-asserted-by":"crossref","first-page":"110667","DOI":"10.1016\/j.mce.2019.110667","article-title":"Pharmacological chaperones of ATP-sensitive potassium channels: mechanistic insight from cryoEM structures","volume":"502","author":"Martin","year":"2020","journal-title":"Mol Cell Endocrinol"},{"key":"2023062723545057100_euad154-B52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yjmcc.2020.04.027","article-title":"A distinct molecular mechanism by which phenytoin rescues a novel long QT 3 variant","volume":"144","author":"Gando","year":"2020","journal-title":"J Mol Cell Cardiol"},{"key":"2023062723545057100_euad154-B53","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1161\/01.CIR.0000160853.19867.61","article-title":"Mouse model of SCN5A-linked hereditary Lenegre\u2019s disease: age-related conduction slowing and myocardial fibrosis","volume":"111","author":"Royer","year":"2005","journal-title":"Circulation"},{"key":"2023062723545057100_euad154-B54","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1093\/cvr\/cvaa082","article-title":"Heritable arrhythmia syndromes associated with abnormal cardiac sodium channel function: ionic and non-ionic mechanisms","volume":"116","author":"Rivaud","year":"2020","journal-title":"Cardiovasc Res"},{"key":"2023062723545057100_euad154-B55","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1139\/y11-070","article-title":"Multiple arrhythmic syndromes in a newborn, owing to a novel mutation in SCN5A","volume":"89","author":"Calloe","year":"2011","journal-title":"Can J Physiol Pharmacol"}],"container-title":["Europace"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/europace\/article-pdf\/25\/6\/euad154\/50725534\/euad154.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/europace\/article-pdf\/25\/6\/euad154\/50725534\/euad154.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T19:56:03Z","timestamp":1687895763000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/europace\/article\/doi\/10.1093\/europace\/euad154\/7208899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":55,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6,2]]}},"URL":"https:\/\/doi.org\/10.1093\/europace\/euad154","relation":{},"ISSN":["1099-5129","1532-2092"],"issn-type":[{"value":"1099-5129","type":"print"},{"value":"1532-2092","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6]]},"published":{"date-parts":[[2023,6]]},"article-number":"euad154"}}